Dr Ravaud speaks with ecancertv at ESMO 2016 about results from a one-year trial of sunitinib vs placebo for post-nephrectomy high-risk renal cancer patients.

This phase III trial found a longer disease-free survival in the sunitinib arm, and Dr Ravaud describes this extension with the manageable toxicity profile as recommending factors for sunitinib in adjuvant therapy.

Dr Ravaud first presented these results at a press conference, with video available here, and the data is available in ecancer news coverage here.